Browse drugs

…Background Atezolizumab plus bevacizumab (Atez/Bev) has become the first-line therapy f…

…Background Combination immunotherapies such as atezolizumab plus bevacizumab (Atez/Bev) and durvalumab plus tremelimumab (D…

…cizumab MVASI (25 mg/mL), ranibizumab Ranivisio (0.6 mg/mL) and faricimab Vabysmo (120 mg/mL) stored in silicone-free and oil-free polypropylene …

…remains uncertain.Therapy with trifluridine/tipiracil (TAS) and bevacizumab (TAS+BEV) has been evaluated in phase III SUNLIGHT trial, demon…

…tion therapy with anti-VEGF agents (aflibercept, bevacizumab or faricimab) and one eye received three treatments.The average number of ad…

…64.4%) AT and 25 (55.6%) HP.The AT most frequently involved was paclitaxel (50; 11.3%), followed by cyclophosphamide (37; 8.4%), doxorubic…

…. The median number of prior treatment lines was four. Prior to fruquintinib, 22 patients had received TAS-102 plus bevacizumab, eight recei…

…Background The combination of atezolizumab and bevacizumab (ATZ/BVZ) therapy has significantly advanced th…

…ycles of adjuvant chemotherapy with cisplatin, temozolomide and bevacizumab. Subsequently, progressive respiratory symptoms led to the disc…

…nd molecular determinants of pseudo-stability/progression after atezolizumab with and without bevacizumab across several histologies.Methods…

…, the patients will receive CapeOX combined with sintilimab and IBI305 at the recommended phase II dose. The primary objectives will b…

…ounded 60 bags of 19 different drugs, including 5-fluorouracil, bevacizumab, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubic…